These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
259 related articles for article (PubMed ID: 11158019)
1. Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. Robbins RJ; Tuttle RM; Sharaf RN; Larson SM; Robbins HK; Ghossein RA; Smith A; Drucker WD J Clin Endocrinol Metab; 2001 Feb; 86(2):619-25. PubMed ID: 11158019 [TBL] [Abstract][Full Text] [Related]
2. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? Mazzaferri EL; Kloos RT J Clin Endocrinol Metab; 2002 Apr; 87(4):1490-8. PubMed ID: 11932270 [TBL] [Abstract][Full Text] [Related]
3. Diagnostic value of recombinant human thyrotropin-stimulated ¹²³I whole-body scintigraphy in the follow-up of patients with differentiated thyroid cancer. Alzahrani AS; AlShaikh O; Tuli M; Al-Sugair A; Alamawi R; Al-Rasheed MM Clin Nucl Med; 2012 Mar; 37(3):229-34. PubMed ID: 22310247 [TBL] [Abstract][Full Text] [Related]
4. Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in the identification of metastasis in differentiated thyroid cancer with 131I planar whole-body imaging and 124I PET. Van Nostrand D; Khorjekar GR; O'Neil J; Moreau S; Atkins FB; Kharazi P; Mete M; Chennupati SP; Burman KD; Wartofsky L J Nucl Med; 2012 Mar; 53(3):359-62. PubMed ID: 22315442 [TBL] [Abstract][Full Text] [Related]
5. Incidence and implications of negative serum thyroglobulin but positive I-131 whole-body scans in patients with well-differentiated thyroid cancer prepared with rhTSH or thyroid hormone withdrawal. Cherk MH; Francis P; Topliss DJ; Bailey M; Kalff V Clin Endocrinol (Oxf); 2012 May; 76(5):734-40. PubMed ID: 22050475 [TBL] [Abstract][Full Text] [Related]
6. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? Robbins RJ; Chon JT; Fleisher M; Larson SM; Tuttle RM J Clin Endocrinol Metab; 2002 Jul; 87(7):3242-7. PubMed ID: 12107232 [TBL] [Abstract][Full Text] [Related]
7. Recombinant human TSH changes the multidisciplinary approach to patients with differentiated thyroid carcinoma. Two-year experience. Giusti M; Zoccola R; Guazzini B; Molinari E; Valenti S; Villa G; Bertolazzi L; Minuto F Minerva Endocrinol; 2003 Sep; 28(3):191-203. PubMed ID: 14605601 [TBL] [Abstract][Full Text] [Related]
8. Sensitivity of preparation with rhTSH or thyroid hormone withdrawal using ¹³¹I-whole body scans to identify metastases of differentiated thyroid cancer. Liepe K Int J Surg; 2015 Apr; 16(Pt A):107-112. PubMed ID: 25771100 [TBL] [Abstract][Full Text] [Related]
9. Recombinant human thyrotropin in follow-up of patients with differentiated thyroid cancer. Podoba J Bratisl Lek Listy; 2010; 111(1):38-40. PubMed ID: 20429310 [TBL] [Abstract][Full Text] [Related]
10. Clinical value of different responses of serum thyroglobulin to recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma. David A; Blotta A; Rossi R; Zatelli MC; Bondanelli M; Roti E; Braverman LE; Busutti L; degli Uberti EC Thyroid; 2005 Feb; 15(2):158-64. PubMed ID: 15753676 [TBL] [Abstract][Full Text] [Related]
11. The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation. Rosario PW; Mineiro Filho AF; Lacerda RX; dos Santos DA; Calsolari MR Thyroid; 2012 Feb; 22(2):113-6. PubMed ID: 22224815 [TBL] [Abstract][Full Text] [Related]
12. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. Pacini F; Molinaro E; Castagna MG; Agate L; Elisei R; Ceccarelli C; Lippi F; Taddei D; Grasso L; Pinchera A J Clin Endocrinol Metab; 2003 Aug; 88(8):3668-73. PubMed ID: 12915653 [TBL] [Abstract][Full Text] [Related]
13. Value of diagnostic radioiodine whole-body scanning after initial therapy in patients with differentiated thyroid cancer at intermediate and high risk for recurrence. Rosario PW; Furtado Mde S; Mineiro Filho AF; Lacerda RX; Calsolari MR Thyroid; 2012 Nov; 22(11):1165-9. PubMed ID: 23050784 [TBL] [Abstract][Full Text] [Related]
14. Serum thyroglobulin concentrations and (131)I whole-body scan results in patients with differentiated thyroid carcinoma after administration of recombinant human thyroid-stimulating hormone. David A; Blotta A; Bondanelli M; Rossi R; Roti E; Braverman LE; Busutti L; degli Uberti EC J Nucl Med; 2001 Oct; 42(10):1470-5. PubMed ID: 11585859 [TBL] [Abstract][Full Text] [Related]
15. High-risk patients with differentiated thyroid cancer T4 primary tumors achieve remnant ablation equally well using rhTSH or thyroid hormone withdrawal. Bartenstein P; Calabuig EC; Maini CL; Mazzarotto R; Muros de Fuentes MA; Petrich T; Rodrigues FJ; Vallejo Casas JA; Vianello F; Basso M; Balaguer MG; Haug A; Monari F; Vaňó RS; Sciuto R; Magner J Thyroid; 2014 Mar; 24(3):480-7. PubMed ID: 24040896 [TBL] [Abstract][Full Text] [Related]
16. Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous and exogenous TSH stimulation. Vrachimis A; Schober O; Riemann B Nuklearmedizin; 2012; 51(3):67-72. PubMed ID: 22294096 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of Low-dose and High-dose Radioactive Iodine Ablation With rhTSH in Korean Patients With Differentiated Thyroid Carcinoma: The First Report in Nonwestern Countries. Joung JY; Choi JH; Cho YY; Kim NK; Sohn SY; Kim SW; Chung JH Am J Clin Oncol; 2016 Aug; 39(4):374-8. PubMed ID: 24732812 [TBL] [Abstract][Full Text] [Related]
18. A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. Kloos RT; Mazzaferri EL J Clin Endocrinol Metab; 2005 Sep; 90(9):5047-57. PubMed ID: 15972576 [TBL] [Abstract][Full Text] [Related]
19. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. Elisei R; Schlumberger M; Driedger A; Reiners C; Kloos RT; Sherman SI; Haugen B; Corone C; Molinaro E; Grasso L; Leboulleux S; Rachinsky I; Luster M; Lassmann M; Busaidy NL; Wahl RL; Pacini F; Cho SY; Magner J; Pinchera A; Ladenson PW J Clin Endocrinol Metab; 2009 Nov; 94(11):4171-9. PubMed ID: 19850694 [TBL] [Abstract][Full Text] [Related]
20. The diagnostic use of the rhTSH/thyroglobulin test in differentiated thyroid cancer patients with persistent disease and low thyroglobulin levels. Pellegriti G; Scollo C; Regalbuto C; Attard M; Marozzi P; Vermiglio F; Violi MA; Cianci M; Vigneri R; Pezzino V; Squatrito S Clin Endocrinol (Oxf); 2003 May; 58(5):556-61. PubMed ID: 12699436 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]